Goldman Sachs Cuts Chemours Stock Price Target on EBITDA Outlook
1 day ago
Goldman Sachs lowered Chemours' price target to $16 from $17, maintaining a Neutral rating based on 2027 earnings estimates. The chemical manufacturer's stock has declined 36% over six months despite a 19% year-to-date recovery.
Show all 119 updates